Form 4: RA Capital Management Acquires Stock Option in Eliem Therapeutics

RA Capital Management, along with related entities and individuals, reported the acquisition of a stock option for 10,000 shares of Eliem Therapeutics.

Summary

• RA Capital Management, L.P., along with related entities and individuals including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah, filed a Form 4.
• The filing reports the acquisition of a stock option (right to buy) 10,000 shares of Eliem Therapeutics, Inc. (ELYM) at an exercise price of $7.89 on June 26, 2024.
• The option vests on the earlier of June 26, 2025, or the day before the next annual meeting of stockholders, contingent upon Dr. Andrew Levin's continuous service.
• Dr. Levin, a Partner and Managing Director of RA Capital Management, holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, and the Account.
• Any proceeds from the exercise of the option will offset advisory fees owed by these entities to RA Capital Management.
• The reporting persons disclaim beneficial ownership of the option and underlying common stock, except to the extent of their respective pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an insider transaction. The acquisition of a stock option can be seen as a positive sign of continued investment, but it's not a major event that would significantly impact sentiment.

Positives

• The acquisition of the stock option indicates a continued investment and interest in Eliem Therapeutics by RA Capital Management.
• The vesting schedule tied to Dr. Levin's service provides an incentive for his continued involvement with Eliem Therapeutics.

Risks

• The filing indicates a disclaimer of beneficial ownership, suggesting that the reporting persons' direct financial gain from the option is limited to their pecuniary interest.
• The value of the option is dependent on the future performance of Eliem Therapeutics' stock price.

Future Outlook

The document does not contain explicit forward-looking statements regarding Eliem Therapeutics' future performance, but the acquisition of the stock option suggests a continued investment and interest in the company by RA Capital Management.

Industry Context

Form 4 filings are routine disclosures for significant shareholders and insiders, providing transparency into their transactions in a company's stock. RA Capital Management is a well-known healthcare-focused investment firm, so their investment activity in Eliem Therapeutics is relevant to the biotech industry.

Comparison to Industry Standards

• RA Capital Management is a well-known healthcare-focused investment firm, similar to Orbimed Advisors or Baker Bros. Advisors.
• Their investment strategies often involve taking significant positions in biotech companies, as reflected in this filing.
• The acquisition of stock options is a common practice for incentivizing board members and aligning their interests with those of the shareholders, similar to option grants at companies like Amgen or Gilead.

Stakeholder Impact

• The acquisition of the stock option could have a slightly positive impact on shareholders, as it signals continued investment and confidence in Eliem Therapeutics by RA Capital Management.
• The vesting schedule tied to Dr. Levin's service could positively impact employees, as it incentivizes his continued involvement with the company.

Key Dates